Navigation Links
Europe to tackle brain disorder research by linking industry, academia
Date:11/27/2007

Attempts to cure brain-related disorders have proved less successful than therapies for other major conditions such as heart cancer, even though just as many people suffer from them. About 600 million worldwide each year are afflicted by depression alone, more than any other condition except heart disease, and yet of those given existing drugs, only half recover.

Furthermore progress treating depression as well as other major brain disorders has stalled. This stark fact lies behind an ambitious European proposal to revive the field. The proposal, to be presented at EuroBioForum, in Lisbon in December 2007, aims to develop a ground breaking multi-disciplinary research project which would propel Europe to the head of global research into the crucial role of neurotransmitters in brain disorders. Bringing together the relevant specialisms in chemistry, radio-chemistry, in vivo modelling, and above all PET and SPECT scanning, the project would exploit recent advances both in PET (Positron Emission Tomography), and SPECT (Single Photon Emission Computer Tomography), enabling metabolic activity such as levels of neurotransmitters to be determined with greater accuracy in space and quantity.

The objective is to develop new methods to identify the release of neurotransmitters such as noradrenaline, serotonin, acetylcholine, and endorphins, in the brain and so examine their role in major brain disorders. This in turn will enable more effective therapies to be developed than current drugs, which often fail to work, according to the projects leader David Nutt, Professor of Psychopharmacology at the University of Bristol, UK. Professor Nutt is presenting his vision for this groundbreaking project at the EuroBioForum conference, which is organised by the European Science Foundation (ESF) with support from the European Commission.

The programme has great potential for human health given the vast number of people affected, but as Professor Nutt poi
'/>"/>

Contact: Dr. Fiona Kernan
fkernan@esf.org
33-388-762-180
European Science Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Europe-wide Researchers Night
6. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
7. Launch of second European Cancer Research Funding survey
8. Cancer control in Europe works; now it is time to extend it to poorer countries
9. Political decisions harming cancer treatment in Europe
10. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
11. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Within3 Expands into Mobile Applications 2Congressman Fattah Supports Legislation to Address More Funds for Pancreatic Cancer Research 60857 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 2Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 3Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 2